1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018) - Garon, E B; Wong, D J; Schneider, J G; Aljumaily, R; Korn, W M; Patel, M R; Autio, K A; Papadopoulos, K P; Naing, A; Gabrail, N; Munster, P N; Goldman, J; et al.